Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age. The Na...

Full description

Bibliographic Details
Main Authors: Robyn Harrison, Robert Stirling, Oliver Baclic, Wendy Vaudry
Format: Article
Language:English
Published: Public Health Agency of Canada 2020-02-01
Series:Canada Communicable Disease Report
Subjects:
national advisory committee on immunization
naci
imd
meningococcal vaccine
guidance
Online Access:https://doi.org/10.14745/ccdr.v46i23a03

Internet

https://doi.org/10.14745/ccdr.v46i23a03

Similar Items